本帖最后由 老马 于 2012-1-13 21:20 编辑
- a }: G/ i$ E4 d1 t' ?
; m! ?6 k0 c# n6 I2 H* h爱必妥和阿瓦斯丁的比较" G; y2 S' T1 U4 f: B/ q; ]
5 c/ ~% g; Y1 q3 R3 P
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/6 W4 z5 ]5 Y8 Y% h$ O* r5 T& o
, p/ ?6 I* [6 l0 m& o
, {" [* w; s/ p/ k( A% A; v6 mhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial// u+ m* P0 u" a0 a
==================================================- U4 n2 m% u" _1 ]7 Q9 W, r0 j' P
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL): ~0 U/ P7 P% e$ f+ L
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.% {) C6 \! l5 @! u! z( Q
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
" f4 W* R5 X8 R0 E! Y5 L: d
|
显身卡
